Spectral Med Inc is seeing a significant rise in its stock price, reflecting positive investor sentiment.
Spectral Med Inc (EDT.TO) is up today, gaining 4.50% to close at CA$1.16. This increase comes as the company makes steady progress in its regulatory efforts and financial updates, likely sparking renewed interest from investors.
Advertisement
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeMarket cap
$325.84M
52W high
$1.65
52W low
$1.03
1W change
-5.53%
Beta
0.22
Analyst Price Targets
Based on analyst covering EDT · as of Sep 17, 2026
Wall Street analysts forecast EDT stock price to rise 183.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+183.8% Upside
Current Price
C$1.11
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
50.5%
Annualized
90-Day Vol
37.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.93
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.05 | C$0.88 – C$1.25 |
| 60 trading days | C$0.99 | C$0.77 – C$1.26 |
| 90 trading days | C$0.93 | C$0.69 – C$1.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should think about how Spectral Med's recent updates might impact its future as it approaches important regulatory milestones.
Spectral Med Inc sees a 4.50% increase in stock price today
With a market cap of CA$340.5 million, Spectral Med's rising stock shows growing confidence from investors in its future.
Bull case
The recent update from the FDA suggests a smooth regulatory path for Toraymyxin™ (PMX), which could boost market confidence and lead to potential revenue growth.
Bear case
Despite the positive movement, the absence of immediate financial performance metrics and ongoing market volatility could pose risks for investors.
Advertisement
Recent Developments Fueling Growth
The increase in Spectral Med's stock is largely due to recent updates on its PMA application for Toraymyxin™ (PMX). The FDA's feedback during the 100-Day Meeting indicated that no additional trials are needed, which is promising for the company's regulatory timeline. Investors are likely feeling optimistic about a smoother path to market.
Market Sentiment and Future Outlook
With a market capitalization of CA$340.5 million, Spectral Med is in a niche sector that could experience significant growth. As the company continues to advance its PMX product, investor sentiment seems positive, suggesting that further gains may be possible if the company meets its upcoming milestones. For more insights, check out our detailed analysis of EDT.TO.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
